Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Today's Top SOA Links


Wockhardt launches generic version of anti-convulsant drug Lamictal XR®

PARSIPPANY, N.J. and MUMBAI, India, Jan. 8, 2013 /PRNewswire/ -- Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 25mg, 50mg, 100mg, 200mg and 300mg extended release tablets of Lamotrigine, which is used in treatment of epilepsy. Lamotrigine is the generic name for the brand Lamictal XR®, marketed in the United States by Glaxo SmithKline. Wockhardt is launching the product immediately and will be amongst the earliest generic versions of this product in the market.

(Logo:  http://photos.prnewswire.com/prnh/20120615/NY25710LOGO )

"We are continuing our rapid momentum of 2012 into the New Year with this approval of Lamotrigine extended release tablets," said Dr. Habil Khorakiwala, Wockhardt Founder Chairman & Group CEO. "This is the sixth product with drug delivery technology that has received US FDA approval in the last 5 months, a continuing testimony to the R&D capabilities of Wockhardt," he said.

According to IMS Health, the total market for this product in the US is about $250 million. Lamotrigine is used extensively in management of epilepsy. Wockhardt already markets several other products in the United States in the CNS segment, especially anti-convulsant drugs.

In the US generic pharmaceutical market, Wockhardt has been consistently growing market shares for all its products. In many instances, Wockhardt, by virtue of being amongst the few players to market technically challenging products has reaped the advantage of being an early entrant.

Wockhardt will be manufacturing the extended-release tablets of Lamotrigine at its facility in Aurangabad, India. The technology for the extended release tablets was developed in-house.

About Wockhardt:

Wockhardt is a high-technology intensive global pharmaceutical and biotechnology company with multi-disciplinary and innovative R&D programmes. It has 3 research centres globally and manufacturing facilities across India, USA, UK and Ireland. Wockhardt has a significant presence in USA, Europe and India, with 81% of its global revenues coming from international businesses. With a large pool of Patents and Intellectual Property knowhow, Wockhardt is home to 578 scientists, of whom 80 are doctorates. In all, Wockhardt has 169 Patents granted worldwide. In biotechnology research, it has built a competent 'Concept to Market' capabilities in all facets of development and manufacture of recombinant biopharmaceuticals. Wockhardt boasts of a multi-ethnic workforce of more than 7,900 people from 21 different nationalities.

Lamictal XR® is a registered trademark of Glaxo SmithKline.

Visit us at: www.wockhardt.com

Contact: Gopal Venkatesan, 973-257-4975

SOURCE Wockhardt USA

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Web 2.0 Latest News
Change is constant, and over the last decade the nexus of two trends in particular has transformed the enterprise. Mobile technology and cloud software are fundamentally changing the way we interact internally within businesses, and externally with partners and customers. Never befor...
So congratulations, somehow you've managed to wangle your way onto one of the many DevOps conferences being held around the world. Why not you might say? DevOps is not only hot it's the approach many enterprises are now exploring as the means to help accelerate the delivery of high qua...
What does the data landscape look like at Facebook with its 1.3 billion users across the globe? They classify small data referring to OLTP-like queries that process and retrieve a small amount of data, usually 1-1000 objects requested by their …
If you thought the Bring Your Own Device (BYOD) craze was a headache, just wait until button cameras, smart watches, and spy glasses (already here) are a daily occurrence in the office. Workplace #Wearables will be a huge challenge in the coming years as more devices, clothing and pret...
It does not take much to understand the benefits of the DevOps culture, processes, and tools. However, implementing DevOps in your organization is not as obvious and usually involves more than simply setting up tools. You have to convince team members, map old processes to new, and ma...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE